# iOncologi

Source: https://onco.cc/companies/ioncologi/  
OnCo record `ioncologi` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

iOncologi is a Florida company using RNA in layered fat particles to train the immune system against solid tumours. Its first programme is in an early trial in glioblastoma.

## Summary

iOncologi, Inc., a clinical-stage company in Gainesville, Florida, develops RNA immunotherapies under a patent exclusively licensed from the University of Florida Research Foundation. Its multilamellar RNA nanocomplex platform delivers RNA in layered lipid particles to prime a broad immune response; IONC102 pairs the platform with off-the-shelf antigens optimised with SandboxAQ and is in phase 1 in glioblastoma, according to the company. A 2026 National Cancer Institute STTR award funds iOi7, an autologous, ex vivo-expanded immunomodulatory haematopoietic stem cell therapy, for immune checkpoint inhibitor-resistant glioblastoma, including a move to closed, scalable manufacturing.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: iOncologi, Inc.; iOncologi Inc
- HQ: Gainesville, FL
- Type: biotech
- Website: https://ioncologi.com/

## Notes

- Company website and the NIH RePORTER record read on 4 November 2026. The glioblastoma trial the website describes was not matched to a registry record in OnCo.

## Sources

- Official website: https://ioncologi.com/
- NIH RePORTER: award 4R42CA302331-02: https://reporter.nih.gov/project-details/11457448

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/)
- drugs: [IONC102](https://onco.cc/drugs/ionc102/)

---
JSON: https://onco.cc/api/v1/entities/ioncologi.json